1. ALLA AKTIER
  2. NYHETER
  3. XSPRAY PHARMA

Xspray Pharma

Nyheter Xspray Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed

Xspray Pharma AB (publ) today announces the outcome of the subscription of options in the incentive program approved at the Annual General Meeting on May 19, 2022. The long-term incentive program 2022 (LTI 2022) in the form of warrants and employee stock options was fully subscribed, in total 421,875 options will be issued. All members of the management team subscribed to their respective share of the program.

The strike price amounts to SEK 132.20 per share.

Maximum dilution of the share upon full utilization of the warrants amounts to 2,0 percent based on the current number of shares.

For further information, please contact:

Christina Malmberg Hägerstrand
Senior Vice President Communications & Investor Relations
Xspray Pharma AB
Mob: +46 (0) 72 855 93 29
E-mail: christina.malmberg.hagerstrand@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.
 
The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021.
 
The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com

Attachments

Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed

Datum 2022-06-09, kl 08:30
Källa MFN
Bifogade filer
Xspray Pharma’s long-term incentive program LTI 2022 fully subscribed